Clinical Outcomes After Personalized Dosimetry for 90 Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.123.267035 ↗Kurz gefasst
Kommentar in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Michael C Soulen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; and michael.soulen@pennmedicine.upenn.edu. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Embolization, Therapeutic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
In the United States, 90Y microspheres have been approved for more than 20 y for treatment of hepatic malignancies. Glass microspheres (TheraSphere; Boston Scientific) received a humanitarian device exemption for treatment of hepatocellular carcinoma (HCC) from the Food and Drug Administration (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Interventional Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; and michael.soulen@pennmedicine.upenn.edu.
- Interventional Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Zitieren
APA
Soulen, M. C., & Rilling, W. S. (2024). Clinical Outcomes After Personalized Dosimetry for 90 Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.267035
Vancouver
Soulen MC, Rilling WS. Clinical Outcomes After Personalized Dosimetry for 90 Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.267035
BibTeX
@article{Soulen2024,
author = {Soulen, Michael C and Rilling, William S},
title = {Clinical Outcomes After Personalized Dosimetry for 90 Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.123.267035}
}
EUVIMED